-The Indian Express Trendsetters & tweakers Act one Chhattisgarh already has a food security law in place. It became last December the first state to pass a food security bill, which covers several sections not under existing schemes. The Act makes food entitlement a right and depriving anyone of that an offence. If PDS grains, for instance, are being diverted, the officials involved will face penal provisions. The Act also seeks to empower women...

-The Business Standard Govt should streamline its free medicines plan The Centre is reportedly going to shelve a plan to procure generic drugs for free supply to patients throughout the country. This is a serious error. Reportedly, states will instead be asked to do so; but, if a perceived inability to procure, stock and distribute these drugs is the reason for backtracking on the plan, how precisely will states be free of...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...

-The Times of India MUMBAI: A Mumbai hospital has put up a notice advising its doctors to avoid prescribing drugs manufactured by Ranbaxy Laboratories. This comes a fortnight after Ranbaxy Laboratories agreed to pay a $500-million penalty to US authorities for "selling adulterated drugs" in the American market. It is not known whether the two are linked. Consultants at Jaslok Hospital said an advisory was put up at the receptionist's circular desk...

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...